Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer

Anti-Cancer Drugs

Volumn 9, Issue 1, 1998, Pages 51-57

  Kurbacher, Christian M ^a   Cree, Ian A ^b   Bruckner, Howard W ^c   Brenne, Ursula ^a   Kurbacher, Jutta A ^d   Müller, Karin ^a   Ackermann, Tonja ^a   Gilster, Tobias J ^a   Wilhelm, Lucas M ^a   Engel, Heike ^a   Mallmann, Peter K ^a   Andreotti, Peter E ^e  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d St Marien Hospital   (Germany)

^e Atl Scientific Development Inc   (United States)

Author keywords

ATP tumor chemosensitivity assay (ATP TCA); Individualized chemotherapy; Platinum resistance; Recurrent ovarian carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; MITOXANTRONE; PACLITAXEL; TREOSULFAN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LUMINESCENCE; OVARY CARCINOMA; PRIORITY JOURNAL; RECURRENT CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; SALVAGE THERAPY; TUMOR CELLS, CULTURED;

EID: 0004464881     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199801000-00006     Document Type: Article

References (28)

1. Canistra SA. Cancer of the ovary. New Engl J Med 1993; 329: 1550-9.
2. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer. An overview of randomised clinical trials. Br Med J 1991; 303: 884-93.
3. Thigpen JT, Vance RB, Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 1993; 71: 1559-64.
4. Blackledge G, Lawton F, Redman C, Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications of patient treatment and the design of phase II trials. Br J Cancer 1989; 59: 650-3.
5. Ozols RF, Rubin SC, Dembo AJ, Robboy S. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and practice of gynecologic oncology. Philadelphia: Lippincott 1992: 731-81.
6. Guastalla JP. Second-line chemotherapy in epithelial ovarian carcinoma. Platinum again? Taxanes? How to choose? Eur J Cancer 1994; 30A: 1741-4.
7. Bellamy WT. Prediction of response to drug therapy of cancer: a review of in vitro assays. Drugs 1992; 44: 690-708.
8. Von Hoff DD. He's not going to talk about in vitro predictive assays again, is he? J Natl Cancer Inst 1990; 82: 96-101.
9. Von Hoff DD, Sandbach JF, Clark GM, et al. Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst 1990; 82: 110-6.
10. Von Hoff DD, Kronmal R, Salmon SE, et al. A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer. Cancer 1991; 67: 20-7.
11. Cree IA, Kurbacher CM. Individualizing chemotherapy for solid tumors - is there any alternative? Anti-Cancer Drugs 1997; 8: 541-8.
12. Andreotti PE, Cree IA, Kurbacher CM, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55: 5276-82.
13. Cree IA, Kurbacher CM, Untch M, et al. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anti-Cancer Drugs 1996; 7: 630-5.
14. Untch M, Crohns C, Konecny G, et al. Correlation of in vitro tumor chemosensitivity assay with outcome in ovarian cancer patients given carboplatin and cyclophosphamide. Proc Am Soc Clin Oncol 1996; 15: 302 (abstr).
15. Andreotti PE, Kurbacher CM, Lee JM, Greenspan EM, Bruckner HW. Sensitivity of clinical ovarian cancer specimens to the combination of cisplatin and cytosine arabinosine: evaluation by ATP bioluminescence assay. Proc Am Ass Cancer Res 1994; 35: 201 (abstr).
16. Bruckner HW, Lee JM, Runowicz CD, et al. ATP luminescence assay tests the sensitivity of human tumors to adriamycin, taxol, cisplatin, and the combinations. Proc Am Ass Cancer Res 1994; 35: 201 (abstr).
17. Bruckner HW, Kurbacher CM, Mandeli J, Cuttner J. In vitro testing of human ovarian and breast cancers identifies new modulators of taxol and cisplatin. Proc Am Ass Cancer Res 1995; 36: 390 (abstr).
18. Kurbacher CM, Bruckner HW, Cree IA, et al. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer laboratory study and clinical pilot trial. Clin Cancer Res 1997; 3: 1527-33.
19. Hunter EM, Sutherland LA, Cree IA, Dewar JA, Preece PE, Andreotti PE. Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay. Eur J Surg Oncol 1993; 19: 242-9.
20. Kurbacher CM, Cree IA, Brenne U, et al. Heterogeneity of in vitro chemosensitivity in perioperative breast cancer cells to mitoxantrone versus doxorubicin evaluated by a microplate ATP bioluminescence assay. Breast Cancer Res Treat 1996; 41: 161-70.
21. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-93.
22. Christian MC, Trimble EL. Salvage chemotherapy for epithelial ovarian carcinoma. Gynecol Oncol 1994; 55: S143-50.
23. Brown E, Markman M. Tumor chemosensitivity and chemoresistance assays. Cancer 1996; 77: 1020-5.
24. Cree IA, Pazzagli M, Mini E, et al. Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay. Anti-Cancer Drugs 1995; 6: 398-404.
25. Petty RD, Sutherland IA, Hunter EM, Cree IA. Comparison of MTT and ATP-based assays for the measurement of viable cell number. J Biolumin Chemilumin 1995; 10: 29-34.
26. Shpall EJ, Cagnoni PJ, Bearman SI, Purdy MH, Jones RB. High-dose chemotherapy with autologous hematopoietic cell support (AHCS) for the treatment of epithelial ovarian cancer. Proc Am Soc Clin Oncol Educational Book 1995; 14: 360-4.
27. Viens P, Maraninchi D. High-dose chemotherapy and autologous marrow transplantation for common epithelial ovarian carcinoma. In: Armitage JO, Antman KH, eds. High-dose cancer therapy: pharmacology, hematopoeitins, stem cells, 2nd edn. New York: Williams & Wilkins 1995: 847-54.
28. Mainwaring PN, Gore ME. The importance of dose and schedule in cancer chemotherapy: epithelial ovarian cancer. Anti-Cancer Drugs 1995; 6 (suppl 5): 29-41.